Table 3:
Comparison of the HIV-infected children on antiretroviral therapy who tested PCR-positive vs. those who tested PCR-negative
| PCR-positive (N=309) |
PCR-negative (N=7) |
Overall (N=316) |
P | ||
|---|---|---|---|---|---|
| Characteristics at PCR Test | |||||
| Sex, N (%) | 0.7145 | ||||
| Male | 148 (47.9) | 4 (57.1) | 152 (48.1) | ||
| Female | 161 (52.1) | 3 (42.9) | 164 (51.9) | ||
| Age at PCR Test (Category) | 0.6564 | ||||
| 8–10 years, N (%) | 184 (59.6) | 6 (85.7) | 190 (60.1) | ||
| 11–12 years, N (%) | 103 (33.3) | 1 (14.3) | 104 (32.9) | ||
| 13–14 years, N (%) | 22 (7.1) | 0 (0) | 22 (7.0) | ||
| Cohort, N (%) | 0.6825 | ||||
| ESRU | 229 (74.1) | 6 (85.7) | 235 (74.4) | ||
| PHRU | 80 (25.9) | 1 (14.3) | 81 (25.6) | ||
| ART Regimen, N (%) | 0.5489 | ||||
| EFV-based | 168 (54.4) | 5 (71.4) | 173 (54.8) | ||
| LPV-based | 133 (43.0) | 2 (28.6) | 135 (42.7) | ||
| Other-based1 | 8 (2.6) | 0 (0) | 8 (2.5) | ||
| Ever transitioned to EFV, N (%) | 0.2499 | ||||
| Yes | 184 (59.6) | 6 (85.7) | 190 (60.1) | ||
| No | 125 (40.5) | 1 (14.3) | 126 (39.9) | ||
| Viral Load (copies/Ml), N (%) | 1.0000 | ||||
| <50 | 281 (90.9) | 7 (100.0) | 288 (91.1) | ||
| 50–399 | 10 (3.2) | 0 (0) | 10 (3.2) | ||
| ≥400 | 18 (5.8) | 0 (0) | 18 (5.7) | ||
| CD4+ T-cell Count (cells/mm3) | 0.2891 | ||||
| Median | 924 | 749 | 922 | ||
| IQR | 734–1147 | 420–1113 | 727–1147 | ||
| Missing, N (%) | 1 (0.3) | 0 (0) | 1 (0.3) | ||
| CD4 Percentage (%) | 0.0492 | ||||
| Median | 36.7 | 29.3 | 36.7 | ||
| IQR | 32.0–41.3 | 26.1–37.3 | 31.7–41.2 | ||
| Missing, N (%) | 1 (0.3) | 0 (0) | 1 (0.3) | ||
| Virologic Control in Study Up to PCR (copies/Ml) | 0.0115 | ||||
| All <50 | 57 (18.5) | 5 (71.4) | 62 (19.6) | ||
| Ever ≥50, all <400 | 126 (40.8) | 2 (28.6) | 128 (40.5) | ||
| Ever ≥400, all <1000 | 49 (15.9) | 0 (0) | 49 (15.5) | ||
| Ever ≥1000 | 77 (24.9) | 0 (0) | 77 (24.4) | ||
| Characteristics at Time of ART Start | |||||
| Age at ART Start (months) | 0.0007 | ||||
| Median | 6.1 | 2.0 | 6.0 | ||
| IQR | 3.6–12.4 | 1.7–3.6 | 3.5–12.3 | ||
| Age at ART Start (months), N (%) | 0.0008 | ||||
| ≤2 | 39 (12.6) | 5 (71.4) | 44 (13.9) | ||
| 3 | 34 (11.0) | 0 (0) | 34 (10.8) | ||
| 4 | 30 (9.7) | 2 (28.6) | 32 (10.1) | ||
| 5–6 | 56 (18.1) | 0 (0) | 56 (17.7) | ||
| 7–8 | 31 (10.0) | 0 (0) | 31 (9.8) | ||
| 9–12 | 43 (13.9) | 0 (0) | 43 (13.6) | ||
| 13–24 | 73 (23.6) | 0 (0) | 73 (23.1) | ||
| 25–32 | 3 (1.0) | 0 (0) | 3 (1.0) | ||
| Starting Regimen, N (%) | 1.0000 | ||||
| LPV/r-based | 260 (84.1) | 6 (85.7) | 266 (84.2) | ||
| NVP-based | 4 (1.3) | 0 (0) | 4 (1.3) | ||
| RTV-based | 44 (14.2) | 1 (14.3) | 45 (14.2) | ||
| Other (ABC, AZT, 3TC) | 1 (0.3) | 0 (0) | 1 (0.3) | ||
| Pre-ART VL (copies/Ml), N (%) | 0.5474 | ||||
| <100,000 | 24 (9.6) | 12 (16.7) | 253 (9.8) | ||
| 100,000 – 749,999 | 71 (28.5) | 2 (33.3) | 73 (28.6) | ||
| ≥750,000 | 154 (61.9) | 3 (50.0) | 157 (61.6) | ||
| Missing | 60 (19.4) | 1 (14.3) | 61 (19.3) | ||
| Pre-ART CD4 percentage (%), N (%) | 0.7077 | ||||
| <25 | 185 (63.8) | 4 (57.1) | 189 (63.6) | ||
| ≥25 | 105 (36.2) | 3 (42.9) | 108 (36.4) | ||
| Missing | 19 (6.2) | 0 (0) | 19 (6.0) | ||
1.
Other bases for regimens: nevirapine (N=2), bictegravir (N=3), dolutegravir (N=1), atazanavir (N=1), and lamivudine/abacavir only (N=1).
2.
4500 copies/mL
3.
Five children had pre-ART VL ≥ 1000 and <10,000 copies/mL and two children <1000 copies/mL